|
1
|
Harris KM, Spirito P, Maron MS, Zenovich
AG, Formisano F, Lesser JR, Mackey-Bojack S, Manning WJ, Udelson JE
and Maron BJ: Prevalence, clinical profile, and significance of
left ventricular remodeling in the end-stage phase of hypertrophic
cardiomyopathy. Circulation. 114:216–225. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
O'Hanlon R, Grasso A, Roughton M, Moon JC,
Clark S, Wage R, Webb J, Kulkarni M, Dawson D, Sulaibeekh L, et al:
Prognostic significance of myocardial fibrosis in hypertrophic
cardiomyopathy. J Am Coll Cardiol. 56:867–874. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Vasquez C and Morley GE: The origin and
arrhythmogenic potential of fibroblasts in cardiac disease. J
Cardiovasc Transl Res. 5:760–767. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Ho SY, Jackson M, Kilpatrick L, Smith A
and Gerlis LM: Fibrous matrix of ventricular myocardium in
tricuspid atresia compared with normal heart. A quantitative
analysis. Circulation. 94:1642–1646. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Farah MC, Castro CR, Moreira VM, Binotto
MA, Guerra VC, Riso AA, Marcial MB, Lopes AA, Mathias W Jr and
Aiello VD: The impact of preexisting myocardial remodeling on
ventricular function early after tetralogy of Fallot repair. J Am
Soc Echocardiogr. 23:912–918. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Burns KM, Byrne BJ, Gelb BD, Kühn B,
Leinwand LA, Mital S, Pearson GD, Rodefeld M, Rossano JW, Stauffer
BL, et al: New mechanistic and therapeutic targets for pediatric
heart failure: Report from a National Heart, Lung, and Blood
Institute working group. Circulation. 130:79–86. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Moon JC, Messroghli DR, Kellman P,
Piechnik SK, Robson MD, Ugander M, Gatehouse PD, Arai AE, Friedrich
MG, Neubauer S, et al: Society for Cardiovascular Magnetic
Resonance Imaging; Cardiovascular Magnetic Resonance Working Group
of the European Society of Cardiology: Myocardial T1 mapping and
extracellular volume quantification: A Society for Cardiovascular
Magnetic Resonance (SCMR) and CMR Working Group of the European
Society of Cardiology consensus statement. J Cardiovasc Magn Reson.
15:922013. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Cheitlin MD, Robinowitz M, McAllister H,
Hoffman JI, Bharati S and Lev M: The distribution of fibrosis in
the left ventricle in congenital aortic stenosis and coarctation of
the aorta. Circulation. 62:823–830. 1980. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Chowdhury UK, Sathia S, Ray R, Singh R,
Pradeep KK and Venugopal P: Histopathology of the right ventricular
outflow tract and its relationship to clinical outcomes and
arrhythmias in patients with tetralogy of Fallot. J Thorac
Cardiovasc Surg. 132:270–277. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Peters TH, Sharma HS, Yilmaz E and Bogers
AJ: Quantitative analysis of collagens and fibronectin expression
in human right ventricular hypertrophy. Ann N Y Acad Sci.
874:278–285. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Sanchez-Quintana D, Climent V, Ho SY and
Anderson RH: Myoarchitecture and connective tissue in hearts with
tricuspid atresia. Heart. 81:182–191. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Baum J and Duffy HS: Fibroblasts and
myofibroblasts: What are we talking about? J Cardiovasc Pharmacol.
57:376–379. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Rathod RH, Powell AJ and Geva T:
Myocardial fibrosis in congenital heart disease. Circ J.
80:1300–1307. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Mewton N, Liu CY, Croisille P, Bluemke D
and Lima JA: Assessment of myocardial fibrosis with cardiovascular
magnetic resonance. J Am Coll Cardiol. 57:891–903. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Overbeek MJ, Mouchaers KT, Niessen HM,
Hadi AM, Kupreishvili K, Boonstra A, Voskuyl AE, Belien JA, Smit
EF, Dijkmans BC, et al: Characteristics of interstitial fibrosis
and inflammatory cell infiltration in right ventricles of systemic
sclerosis-associated pulmonary arterial hypertension. Int J
Rheumatol. 2010:6046152010.PubMed/NCBI
|
|
16
|
Rohit M, Gupta A and Talwar KK: Heart
failure in children in tropical regions. Curr Heart Fail Rep.
10:277–284. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Ball JD, Williams AW and Davies JN:
Endomyocardial fibrosis. Lancet. 266:1049–1054. 1954. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Ammash NM, Seward JB, Bailey KR, Edwards
WD and Tajik AJ: Clinical profile and outcome of idiopathic
restrictive cardiomyopathy. Circulation. 101:2490–2496. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Krenning G, Zeisberg EM and Kalluri R: The
origin of fibroblasts and mechanism of cardiac fibrosis. J Cell
Physiol. 225:631–637. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Turner NA and Porter KE: Function and fate
of myofibroblasts after myocardial infarction. Fibrogenesis Tissue
Repair. 6:52013. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Banerjee I, Yekkala K, Borg TK and Baudino
TA: Dynamic interactions between myocytes, fibroblasts, and
extracellular matrix. Ann N Y Acad Sci. 1080:76–84. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Sun Y and Weber KT: Infarct scar: A
dynamic tissue. Cardiovasc Res. 46:250–256. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Eyden B: The myofibroblast: Phenotypic
characterization as a prerequisite to understanding its functions
in translational medicine. J Cell Mol Med. 12:22–37. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Shiojima I, Aikawa M, Suzuki J, Yazaki Y
and Nagai R: Embryonic smooth muscle myosin heavy chain SMemb is
expressed in pressure-overloaded cardiac fibroblasts. Jpn Heart J.
40:803–818. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Tomasek JJ, Gabbiani G, Hinz B, Chaponnier
C and Brown RA: Myofibroblasts and mechano-regulation of connective
tissue remodelling. Nat Rev Mol Cell Biol. 3:349–363. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Hinz B: Formation and function of the
myofibroblast during tissue repair. J Invest Dermatol. 127:526–537.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Hinz B: The myofibroblast: Paradigm for a
mechanically active cell. J Biomech. 43:146–155. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Frangogiannis NG, Michael LH and Entman
ML: Myofibroblasts in reperfused myocardial infarcts express the
embryonic form of smooth muscle myosin heavy chain (SMemb).
Cardiovasc Res. 48:89–100. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Hinz B, Pittet P, Smith-Clerc J,
Chaponnier C and Meister JJ: Myofibroblast development is
characterized by specific cell-cell adherens junctions. Mol Biol
Cell. 15:4310–4320. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Weber KT, Sun Y, Bhattacharya SK, Ahokas
RA and Gerling IC: Myofibroblast-mediated mechanisms of
pathological remodelling of the heart. Nat Rev Cardiol. 10:15–26.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
van den Borne SW, Isobe S, Verjans JW,
Petrov A, Lovhaug D, Li P, Zandbergen HR, Ni Y, Frederik P, Zhou J,
et al: Molecular imaging of interstitial alterations in remodeling
myocardium after myocardial infarction. J Am Coll Cardiol.
52:2017–2028. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Krizhanovsky V, Yon M, Dickins RA, Hearn
S, Simon J, Miething C, Yee H, Zender L and Lowe SW: Senescence of
activated stellate cells limits liver fibrosis. Cell. 134:657–667.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Kissin E and Korn JH: Apoptosis and
myofibroblasts in the pathogenesis of systemic sclerosis. Curr
Rheumatol Rep. 4:129–135. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Bataller R and Brenner DA: Liver fibrosis.
J Clin Invest. 115:209–218. 2005. View
Article : Google Scholar : PubMed/NCBI
|
|
35
|
Scotton CJ and Chambers RC: Molecular
targets in pulmonary fibrosis: The myofibroblast in focus. Chest.
132:1311–1321. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Crawford JR, Haudek SB, Cieslik KA, Trial
J and Entman ML: Origin of developmental precursors dictates the
pathophysiologic role of cardiac fibroblasts. J Cardiovasc Transl
Res. 5:749–759. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Biernacka A and Frangogiannis NG: Aging
and cardiac fibrosis. Aging Dis. 2:158–173. 2011.PubMed/NCBI
|
|
38
|
Camici PG, Prasad SK and Rimoldi OE:
Stunning, hibernation, and assessment of myocardial viability.
Circulation. 117:103–114. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Auerbach MA, Schöder H, Hoh C, Gambhir SS,
Yaghoubi S, Sayre JW, Silverman D, Phelps ME, Schelbert HR and
Czernin J: Prevalence of myocardial viability as detected by
positron emission tomography in patients with ischemic
cardiomyopathy. Circulation. 99:2921–2926. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Delcayre C and Swynghedauw B: Molecular
mechanisms of myocardial remodeling. The role of aldosterone. J Mol
Cell Cardiol. 34:1577–1584. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Weber KT and Brilla CG: Pathological
hypertrophy and cardiac interstitium. Fibrosis and
renin-angiotensin-aldosterone system. Circulation. 83:1849–1865.
1991. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Cohn JN: Myocardial structural effects of
aldosterone receptor antagonism in heart failure. J Am Coll
Cardiol. 50:597–599. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Suzuki G, Morita H, Mishima T, Sharov VG,
Todor A, Tanhehco EJ, Rudolph AE, McMahon EG, Goldstein S and
Sabbah HN: Effects of long-term monotherapy with eplerenone, a
novel aldosterone blocker, on progression of left ventricular
dysfunction and remodeling in dogs with heart failure. Circulation.
106:2967–2972. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Izawa H, Murohara T, Nagata K, Isobe S,
Asano H, Amano T, Ichihara S, Kato T, Ohshima S, Murase Y, et al:
Mineralocorticoid receptor antagonism ameliorates left ventricular
diastolic dysfunction and myocardial fibrosis in mildly symptomatic
patients with idiopathic dilated cardiomyopathy: A pilot study.
Circulation. 112:2940–2945. 2005.PubMed/NCBI
|
|
45
|
Cicoira M, Zanolla L, Rossi A, Golia G,
Franceschini L, Brighetti G, Marino P and Zardini P: Long-term,
dose-dependent effects of spironolactone on left ventricular
function and exercise tolerance in patients with chronic heart
failure. J Am Coll Cardiol. 40:304–310. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Pitt B, Zannad F, Remme WJ, Cody R,
Castaigne A, Perez A, Palensky J and Wittes J: Randomized Aldactone
Evaluation Study Investigators: The effect of spironolactone on
morbidity and mortality in patients with severe heart failure. N
Engl J Med. 341:709–717. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Massagué J: TGF-beta signal transduction.
Annu Rev Biochem. 67:753–791. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Leask A and Abraham DJ: TGF-beta signaling
and the fibrotic response. FASEB J. 18:816–827. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Chen Y, Xu SW, Eastwood M, Black CM,
Denton CP, Leask A and Abraham DJ: Contribution of activin
receptor-like kinase 5 (transforming growth factor beta receptor
type I) signaling to the fibrotic phenotype of scleroderma
fibroblasts. Arthritis Rheum. 54:1309–1316. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Kuwahara F, Kai H, Tokuda K, Kai M,
Takeshita A, Egashira K and Imaizumi T: Transforming growth
factor-beta function blocking prevents myocardial fibrosis and
diastolic dysfunction in pressure-overloaded rats. Circulation.
106:130–135. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Frantz S, Hu K, Adamek A, Wolf J, Sallam
A, Maier SK, Lonning S, Ling H, Ertl G and Bauersachs J:
Transforming growth factor beta inhibition increases mortality and
left ventricular dilatation after myocardial infarction. Basic Res
Cardiol. 103:485–492. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Tan SM, Zhang Y, Connelly KA, Gilbert RE
and Kelly DJ: Targeted inhibition of activin receptor-like kinase 5
signaling attenuates cardiac dysfunction following myocardial
infarction. Am J Physiol Heart Circ Physiol. 298:H1415–H1425. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Campbell SE and Katwa LC: Angiotensin II
stimulated expression of transforming growth factor-beta1 in
cardiac fibroblasts and myofibroblasts. J Mol Cell Cardiol.
29:1947–1958. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Schultz JJ, Witt SA, Glascock BJ, Nieman
ML, Reiser PJ, Nix SL, Kimball TR and Doetschman T: TGF-beta1
mediates the hypertrophic cardiomyocyte growth induced by
angiotensin II. J Clin Invest. 109:787–796. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
De Mello WC and Specht P: Chronic blockade
of angiotensin II AT1-receptors increased cell-to-cell
communication, reduced fibrosis and improved impulse propagation in
the failing heart. J Renin Angiotensin Aldosterone Syst. 7:201–205.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Leask A: Targeting the TGFbeta,
endothelin-1 and CCN2 axis to combat fibrosis in scleroderma. Cell
Signal. 20:1409–1414. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Leask A: Potential therapeutic targets for
cardiac fibrosis: TGFbeta, angiotensin, endothelin, CCN2, and PDGF,
partners in fibroblast activation. Circ Res. 106:1675–1680. 2010.
View Article : Google Scholar : PubMed/NCBI
|
